H-CYTE, Inc. (HCYT)
| Market Cap | 1.06M |
| Revenue (ttm) | 778,137 |
| Net Income (ttm) | -9.55M |
| Shares Out | 477.61K |
| EPS (ttm) | -40.02 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 100 |
| Open | 2.21 |
| Previous Close | 2.21 |
| Day's Range | 2.21 - 2.21 |
| 52-Week Range | 2.02 - 68.80 |
| Beta | 0.79 |
| Analysts | Sell |
| Price Target | n/a |
| Earnings Date | Feb 23, 2023 |
About HCYT
H-CYTE, Inc., a biopharmaceutical company, develops and delivers various treatments for patients with chronic respiratory and pulmonary disorders in the United States. The company develops and implements treatment options in autologous cellular therapy to treat chronic lung disorders. It has a product supply agreement with Rion, LLC to develop and distribute a biologic for chronic obstructive pulmonary disease. The company is headquartered in Tampa, Florida. [Read more]
Financial Performance
In 2021, H-CYTE's revenue was $1.61 million, a decrease of -25.07% compared to the previous year's $2.15 million. Losses were -$4.80 million, -25.70% less than in 2020.
Financial StatementsNews
H-CYTE Completes Acquisition of SkinDisc™ Regenerative Tissue Kit from Scion Solutions, LLC
Wound Healing and Limb Salvage Technology Added to Growing Asset Portfolio Company's Second Completed Transaction in Four Months
H-CYTE Announces Intent to Acquire SkinDisc, Expects to Complete Within 30 Days
Wound Healing and Limb Salvaging Technology Adds to Company's Asset Portfolio Focused on Unmet Medical Needs Wound Healing and Limb Salvaging Technology Adds to Company's Asset Portfolio Focused on Un...
H-CYTE Completes Acquisition of Jantibody
Milestone Achieved as Immunotherapeutic Agent Under Investigation for the Treatment of Ovarian Cancer Added to Asset Portfolio Milestone Achieved as Immunotherapeutic Agent Under Investigation for the...
H-CYTE to Expect the Completed Acquisition of Jantibody Within 30 Days
Addition of Immunotherapeutic Agent Under Investigation for the Treatment of Ovarian Cancer to Asset Portfolio Addition of Immunotherapeutic Agent Under Investigation for the Treatment of Ovarian Canc...
H-CYTE Announces 1-for-1,000 Reverse Stock Split
Strategic Decision to Support Improved Investor Profile and Potential Future Uplisting of Securities to Major Exchange Strategic Decision to Support Improved Investor Profile and Potential Future Upli...
H-CYTE Announces Proceeds of $1.05 Million from Warrant Exercise
Proceeds to Support Inorganic Growth and General Working Capital Purposes Proceeds to Support Inorganic Growth and General Working Capital Purposes
H-CYTE Enters Into Letter of Intent for Acquisition of Catheter Precision, Inc.
Targets one of Healthcare's Largest Multi-Billion Dollar Markets: Cardiac Electrophysiology Targets one of Healthcare's Largest Multi-Billion Dollar Markets: Cardiac Electrophysiology